Pfizer guides for US$61.5bn sales from Covid-19, Paxlovid, Seagen
- Pfizer Inc (NYSE:PFE) said today that it is expecting $58.5 billion to $61.5 billion of sales in 2024 from Covid-19 vaccines, antiviral medicine Paxlovid and Seagen, with deal for the latter cancer drug company imminent. This is higher than its legacy 2024 guidance and slightly above the guidance it gave in October for 2023 sales.
- 12/13/2023
|
8 Tax-Loss Sell Alerts For December
- Investors should consider tax-loss selling before December ends to offset capital gains. Two characteristics to consider for selling stocks are stocks bought at a higher price and broken companies with weak long-term prospects. Stock grades, sentiment, and fundamentals assessed.
- 12/12/2023
|
Pfizer to close Seagen acquisition after donating cancer drug rights
- Pfizer Inc (NYSE:PFE) announced on Tuesday that it will donate the rights of royalties from sales of cancer drug Bavencio to the American Association for Cancer Research (AACR) in order to address concerns from US antitrust regulators related to its pending $43-billion acquisition of Seagen Inc. The big US drugmaker said it now expects to close the acquisition of Seagen on December 14, 2023, subject to the satisfaction of other customary closing conditions. Pfizer noted the waiting period for the Federal Trade Commission to oppose the acquisition expired on Monday.
- 12/12/2023
|
Pfizer gets OK for $43-billion Seagen deal after donating cancer drug rights
- Pfizer said on Tuesday it has agreed to donate the rights of royalties from sales of cancer drug Bavencio to address concerns from U.S. antitrust regulators related to its $43-billion deal to buy Seagen.
- 12/12/2023
|
Pfizer expects to close Seagen deal on Thursday, will create a new oncology division to incorporate company
- Pfizer Inc. PFE, -0.49% said Tuesday it has received all the regulatory approvals needed to close the acquisition of Seagen Inc. SGEN, +1.20% and expects to close the deal on Thursday. To address concerns raised by the Federal Trade Commission, the drug company has agreed to donate the rights of royalties from sales of Bavencio in the U.S. to the American Association for Cancer Research to support it in its mission of curing cancer through research and funding.
- 12/12/2023
|
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
- NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announces that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired December 11, 2023, with respect to Pfizer's pending acquisition of Seagen Inc. (NASDAQ: SGEN). Pfizer and Seagen have now received all required regulatory approvals to complete the acquisition. Pfizer expects to close the acquisition of Seagen on December 14, 2023, subject to the satisfaction of other customary closing con.
- 12/12/2023
|
ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma
- BOTHELL, Wash.--(BUSINESS WIRE)-- #ASH23--Seagen Inc. (NASDAQ: SGEN) today announced that clinically meaningful progression-free survival (PFS), a secondary endpoint, was observed in a Phase 2 study evaluating the antibody-drug conjugate (ADC) ADCETRIS® (brentuximab vedotin) in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine (AN+AD) as first-line treatment for early and advanced stage classical Hodgkin lymphoma (cHL). This is the first time 12-m.
- 12/10/2023
|
TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
- BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced data from the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA® (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla®). The combination showed a statistically significant improvement in progression-free survival (PFS), the study's primary endpoint, in patients with unresectable locally advanced or metastatic human epidermal growth factor receptor 2-positive (HER2-positive) breast c.
- 12/06/2023
|
Why Is Seattle Genetics (SGEN) Down 0.7% Since Last Earnings Report?
- Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock?
- 12/01/2023
|
Seagen's (SGEN) Combo Drug Expanded-Use sBLA Gets Priority Tag
- Seagen (SGEN) and Astellas Pharma announce that the FDA has accepted the label expansion-seeking application for the Padcev/Keytruda combo under priority review to treat first-line bladder cancer.
- 12/01/2023
|
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
- BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE:4503) today announced that on November 30, 2023 the U.S. Food and Drug Administration (FDA) accepted for priority review a supplemental Biologics License Application (sBLA) for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as a combination therapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC), a form of bladder cancer that has.
- 11/30/2023
|
CPRI, SGEN, VMW: Why These 3 Stocks Are on the Tip of Bill Gross' Tongue
- Bill Gross, the eponymous Bond King, is wading into the stock market to advise investors. Worryingly, he pointed to an imminent fourth-quarter recession closing out 2023.
- 11/05/2023
|
Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting
- BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (NASDAQ: SGEN) today announced the first presentation of data evaluating ADCETRIS® (brentuximab vedotin) in combination with an anti-PD-1 checkpoint inhibitor in non-small cell lung cancer (NSCLC) and melanoma, and shared preclinical data for an investigational CD30-directed antibody-drug conjugate (ADC) that uses a novel tripeptide linker. The studies were presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place.
- 11/03/2023
|
This High-Yield Dividend Stock Is a Proven Wealth Creator
- In 2023, the broader market has ignored the deep value proposition of most large-cap pharmaceutical stocks. Pfizer, a stalwart of the industry, has been among the group's worst performers this year.
- 11/02/2023
|
Seagen 3Q revenue beat driven by jump in product sales
- Seagen reported mixed third quarter earnings, with revenue outperforming expectations on strong product sales growth as earnings fell short of estimates. The cancer-focused biotechnology company which is being acquired by Pfizer reported revenue of $649 million for 3Q.
- 11/01/2023
|
Pfizer wins unconditional EU antitrust okay for $43 bln Seagen buy
- U.S. pharmaceutical company Pfizer gained unconditional EU antitrust approval on Thursday for its proposed $43 billion acquisition of cancer drug maker Seagen.
- 10/19/2023
|
5 Stocks That Have Massive Upside According to Analysts
- Analyst ratings are not perfect, but they're one of the better ways for investors to forecast future stock price movement. Here are five stocks that analysts believe have massive upside for patient, long-term investors.
- 09/29/2023
|
Signal Says Buy Calls on This Biotech Stock
- Biotech stock Seagen Inc (NASDAQ:SGEN) scored an all-time high of $215.04 today, building on a Friday breakout from a consolidation between $204 and $210.
- 09/25/2023
|
Seagen's (SGEN) Combo Drug Meets Goals in Bladder Cancer Study
- Seagen (SGEN) announces positive top-line results from its late-stage study of the Padcev/Keytruda combo in the treatment of adult patients with metastatic bladder cancer. The stock of the company rises 3.5%.
- 09/25/2023
|
Seagen-Merck Bladder Cancer Treatment Shows Positive Results; Seagen Shares Jump
- Biotechnology company Seagen Inc. (SGEN) and Tokyo-based Astellas Pharma Inc. on Friday reported positive results from a Phase 3 trial of their experimental bladder cancer medicine, Padcev, in combination with Merck's (MRK) Keytruda.
- 09/22/2023
|
Flee to Healthcare Stocks if Recession Rears its Head?
- If you're looking for a sector that's on sale, look to healthcare. The Health Care Select Sector SPDR Fund NYSEARCA: XLV is down 2.50% in the past month, lagging the S&P 500.
- 09/20/2023
|
EU antitrust regulators set Oct. 19 deadline for Pfizer's Seagen deal
- Pfizer's $43 billion bid for Seagen will be decided by EU antitrust regulators by Oct. 19, a regulatory filing showed on Friday.
- 09/15/2023
|
Zai Lab ADR surges after Seagen, Genmab release cervical cancer treatment results
- Zai Lab Ltd.'s American depositary receipts ZLAB, +2.47% jumped 14% premarket on Tuesday after Seagen Inc. SGEN, +0.89% and Genmab A/S GMAB, +0.24% announced that Tivdak, their treatment for cervical cancer, improved patients' overall survival in a late-stage study.
- 09/05/2023
|
Genmab, Seagen say Tivdak cervical cancer trial met overall survival endpoint
- Genmab A/S , and Seagen Inc on Monday said that the Phase III trial of Tivdak in recurrent or metastatic cervical cancer patients on or after front-line therapy met its primary endpoint of overall survival.
- 09/04/2023
|
Seagen's (SGEN) Breast Cancer Study on Tuksya Combo Meets Goal
- Seagen (SGEN) announces positive top-line results from its breast cancer study evaluating Tuksya in combination with Roche's Kadcyla.
- 08/17/2023
|
Seagen's breast cancer therapy meets main goal in late-stage study
- Seagen said on Wednesday its breast cancer therapy in combination with Roche's Kadcyla helped extend the time patients lived without their disease progressing in a late-stage trial.
- 08/16/2023
|
3 Pharmaceutical Stocks to Buy and Hold for the Long Haul
- There's a reason why many investors own one or more pharmaceutical stocks. This is a $1.2 trillion industry that is essential to the quality of life for many people.
- 08/12/2023
|
3 Healthcare Stocks With Healthy Dividends
- The stocks' shares have all declined to begin the year. Each company had a sluggish first quarter, but has a pipeline with plenty of potential.
- 07/13/2023
|
Drugmakers' deal making will plow ahead despite antitrust scrutiny, analysts say
- The brisk pace of biopharmaceutical deal making seen in the first half of this year may only accelerate in the months ahead, even as regulators take a hard look at some of the bigger deals, analysts say.
- 07/12/2023
|
Best Under-the-Radar Stocks: 3 That AI Predicts Will Soar in July
- Under-the-radar stocks have provided compelling returns in 2023. Indeed, the rally this year has been mostly concentrated in a few key sectors, such as technology and artificial intelligence.
- 07/04/2023
|
FTC Wants to Block the Amgen-Horizon Deal: Is Pfizer's Acquisition of Seagen at Risk, Too?
- There isn't much overlap between Amgen's business and Horizons', but that isn't stopping the FTC from looking to block the deal. Pfizer has a strong oncology portfolio and is planning to acquire Seagen, a company with an entire focus on cancer treatments.
- 05/24/2023
|
Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?
- Pfizer Inc. NYSE: PFE continued its downward trajectory on May 17, following news that the Federal Trade Commission is seeking to block Amgen Inc.'s NASDAQ: AMGN planned acquisition of Horizon Therapeutics Plc NASDAQ: HZNP.
- 05/19/2023
|
Pfizer to raise $31 billion in debt offering to fund Seagen acquisition, SEC filing shows
- The debt offering by Pfizer to buy cancer drug maker Seagen comes as Apple, Merck and T-Mobile tap the U.S. bond market ahead of the debt ceiling standoff.
- 05/17/2023
|
Pfizer (PFE) to Raise $31B in Debt to Fund Seagen (SGEN) Deal
- Pfizer (PFE) offers bonds worth $31 billion to fund its pending acquisition of cancer drugmaker, Seagen (SGEN).
- 05/17/2023
|
Pfizer Prices $31 Billion Debt Offering to Fund Seagen Acquisition
- Pfizer's acquisition of cancer-focused biotech Seagen, announced in March, would be its biggest since 2009. The deal faces risks.
- 05/17/2023
|
Seagen (SGEN) Stock Falls 6% After Director Sells Shares
- Seagen (NASDAQ: SGEN ) stock is slipping on Tuesday after one of the company's directors sold some of their shares. According to a filing with the Securities and Exchange Commission (SEC), Seagen director Daniel Welch sold 1,864 shares of SGEN stock.
- 05/16/2023
|
Horizon Tumbles — Taking Seagen, Prometheus With It — On Reports FTC Could Block Its Amgen Takeover
- Reports the FTC could block Amgen's takeover of Horizon reverberated across biotech stocks on Tuesday, with HZNP stock's crash leading the way. The post Horizon Tumbles — Taking Seagen, Prometheus With It — On Reports FTC Could Block Its Amgen Takeover appeared first on Investor's Business Daily.
- 05/16/2023
|
Seattle Genetics (SGEN) Reports Q1 Loss, Lags Revenue Estimates
- Seattle Genetics (SGEN) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $0.74 per share a year ago.
- 04/27/2023
|
Consider This Undervalued Pharma Giant Before Its Blockbuster Deal Closes
- Pfizer's cash deal for Seagen benefits shareholders. Seagen's pipeline of antibody-drug conjugates (ADCs) looks promising.
- 04/17/2023
|
Seagen to Report First Quarter 2023 Financial Results on April 27, 2023
- BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its first quarter 2023 financial results on Thursday, April 27, 2023. Given the recently announced agreement to be acquired by Pfizer Inc., Seagen will not be hosting a conference call. About Seagen Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives.
- 04/07/2023
|
Seagen's (SGEN) Padcev & Keytruda Combo Gets FDA Accelerated Nod
- The FDA grants accelerated approval to Seagen (SGEN) and partner, Astellas' combination therapy of Padcev with Merck's Keytruda for the treatment of first and second-line metastatic urothelial cancer.
- 04/04/2023
|
Seagen founder Clay Siegall is back in biotech as CEO of Purdue University spinout
- Clay Siegall, the Seagen founder who resigned last year following an arrest and allegations of domestic violence, is jumping back into the biotech world as CEO and president of Morphimmune.
- 03/22/2023
|
Why Pfizer Likely Isn't Done With M&A After the Seagen Deal
- Pfizer has been loading up on acquisitions to help strengthen its growth prospects. Acquiring Seagen is a big move for the company, but Pfizer isn't done with M&A yet.
- 03/22/2023
|
3 Dividend Contenders to Buy Now for Long-Term Gains Later
- Dividend contenders are a group of companies that have increased the dividend they pay to shareholders for at least 10 years up to 24 years. There are currently over 360 such companies.
- 03/22/2023
|
1 Top Healthcare Stock That Could Make You Richer in the Next Decade
- Pfizer's dividend has a decent yield right now, and its payout will likely grow. It'll be facing a few stiff headwinds soon, but they aren't relevant in the long term.
- 03/19/2023
|
Why Is Seattle Genetics (SGEN) Up 24.6% Since Last Earnings Report?
- Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock?
- 03/17/2023
|
Should Investors Consider Pfizer (PFE) or Seagen (SGEN) Stock After Acquisition
- Shares of Seagen (SGEN) popped 14% yesterday on news that Pfizer (PFE) would acquire the company for $43 billion. The deal values Seagen shares at $229 and 15% above current levels.
- 03/14/2023
|
Is Pfizer Stock a Screaming Buy After Its $43 Billion Seagen Acquisition?
- Pfizer has been a stock in search of a catalyst all year long. The drugmaker's $43 billion acquisition of Seagen probably isn't the catalyst shareholders were hoping for.
- 03/14/2023
|
Seagen (SGEN) Set to be Acquired by Pfizer for $43 B, Stock Up
- Seagen is set to be acquired by the large-cap pharma company, Pfizer, at a valuation of $43 billion. The stock is up about 15% in response to the news.
- 03/14/2023
|
Strength Seen in Seattle Genetics (SGEN): Can Its 14.5% Jump Turn into More Strength?
- Seattle Genetics (SGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
- 03/14/2023
|
How Pfizer's $43 billion acquisition of Seagen could impact the biotech industry in Seattle
- Biopharma acquisitions often come with layoffs and lab shutdowns as smaller companies get absorbed.
- 03/13/2023
|
Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners
- Markets were mixed on a volatile day on Wall Street. Sanofi offered to buy Provention Bio at a price more than triple where the stock closed Friday.
- 03/13/2023
|
Week Ahead: Banking Crisis, Inflation Reports, and Big Pharma Acquisitions
- Last week ended on a hectic note
- 03/13/2023
|
Pfizer Buys Cancer-Drug Maker Seagen for $43 Billion
- Pfizer Inc. is purchasing cancer-drug maker Seagen Inc. for an enterprise value of $43 billion, using the biggest deal of the year to set its course out of the pandemic and back into mainstream pharma. Pfizer CEO Dr. Albert Bourla speaks to David Westin.
- 03/13/2023
|
Pfizer offers $43 billion to buy cancer drugmaker Seagen
- CNBC's Meg Tirrell joins 'Power Lunch' to discuss Pfizer's acquisition of Seagen, the reasoning behind the $43 billion biotech deal, and more.
- 03/13/2023
|
Pfizer CEO says it will be able to deliver Seagen's cancer therapy at a scale not seen before with $43 billion deal
- Pfizer CEO Albert Bourla said it will deliver Seagen's cancer therapy to the world at a scale that hasn't been seen before with its $43 billion acquisition.
- 03/13/2023
|
Pfizer Overpays for Seagen, but Who's Counting
- Acquiring top biotech assets as other big pharmaceutical companies face a patent cliff was bound to be expensive.
- 03/13/2023
|
Seagen has one of the greatest technologies to battle cancer: Pfizer CEO on acquisition
- Albert Bourla, Pfizer CEO, joins 'Squawk on the Street' to discuss his thoughts on the company buying Seagen.
- 03/13/2023
|
Pfizer Buying Seagen For $43 Billion: Details (PFE) (SGEN)
- Pfizer (NYSE: PFE) is buying Seagen Inc. (Nasdaq: SGEN) for $43 billion. These are the details.
- 03/13/2023
|
Pfizer to pay $43B for Seagen, boosting cancer drug portfolio
- The latest deal comes as Pfizer seeks to mitigate an anticipated $17 billion hit to revenue by 2030 from patent expirations for top drugs and decline in demand for its COVID products.
- 03/13/2023
|
Why Seagen Stock Is Soaring Today
- Pfizer plans to acquire Seagen for around $43 billion. Investors appear to have already been betting the deal would happen after several weeks of rumors about a potential buyout.
- 03/13/2023
|
Seagen Stock Boosted on Billion-Dollar Buyout
- Seagen Inc (NASDAQ:SGEN) stock is soaring today, after news that Pfizer (PFE) is acquiring the company for roughly $43 billion, expanding its access to cancer treatment.
- 03/13/2023
|
Pfizer aiming to acquire Seagen in $43 billion deal
- Yahoo Finance Live's Julie Hyman discusses reports that Pfizer is aiming to acquire Seagen in a $43 billion deal.
- 03/13/2023
|
Regional banks pace decliners, as biotech deals lift Seagen and Provention Bio
- Here are some of the biggest movers on Monday with banks firmly in focus after federal regulators stepped into protect deposits at fallen bank SVB.
- 03/13/2023
|
SGEN Stock Alert: Pfizer Buys Seagen in GIANT $43 Billion Deal
- Seagen (NASDAQ: SGEN ) stock is taking off on Monday as investors react to an acquisition deal with Pfizer (NYSE: PFE ). Pfizer is acquiring Seagen for $43 billion in cash.
- 03/13/2023
|
Pfizer Officially Nabs Seagen For $43 Billion; Provention Soars On Sanofi Deal
- Pfizer will buy Seagen for roughly $43 billion, and Sanofi will buy Provention for $2.9 billion. SGEN stock and PRVB stock soared.
- 03/13/2023
|
Pfizer to purchase Seagen in $43 billion all-cash deal, cancer biotech's stock pops 20%
- Pfizer Inc. PFE, -0.18% plans to acquire cancer biotechnology company Seagen Inc. SGEN, -0.59% in a deal with a $43 billion enterprise value, the companies announced Monday morning. Pfizer intends to pay $229 a share in cash for Seagen, which discovers and develops cancer drugs.
- 03/13/2023
|
Hot Stocks And Hot Wings Serve Up Spicy Breakouts And Buy Zones
- As the market indexes fight for support, ANET, WING, BKNG, CDNS, PANW and more land a spot on the IBD Breakout Stocks Index. The post Hot Stocks And Hot Wings Serve Up Spicy Breakouts And Buy Zones appeared first on Investor's Business Daily.
- 03/08/2023
|
The 5 Best and Worst Performing Large-Cap Stocks in February 2023
- Investing in large-cap stocks is considered one of the best ways to invest in the stock market.
- 03/07/2023
|
These Are the Top 10 Holdings of David Kim
- David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec 2012).
- 03/06/2023
|
U.S. Stock Market Today: Today's Biggest Market Movers
- The stock market is digesting recent inflation data and earnings reports. Where is the stock market headed next?
- 02/27/2023
|
Pfizer Is Eyeing a Deal With Seagen After Merck's Failure
- The biotech industry has a reputation for being a breeding ground for high-value mergers and acquisitions, which does not come as a surprise given the aggressive push by leading biotech companies to consolidate their market position. Seagen Inc. ( SGEN , Financial), a biotech company that develops therapies for cancer treatment, has been the target of several large players in the industry.
- 02/27/2023
|
Fisker, Zillow, Seagen, Union Pacific stocks rise after back-to-back losses for S&P 500
- Yahoo Finance Live's Brad Smith discusses Monday's trending tickers, including Fisker, Zillow, Seagen, and Union Pacific.
- 02/27/2023
|
Durables Goods Sink -4.5%, but Higher on Business Spending
- These Durable Goods figures are preliminary, and subject to future revisions.
- 02/27/2023
|
Seagen stock rises as Pfizer reportedly in talks to acquire Seattle-area biotech giant
- Biopharma giant Pfizer is eyeing an acquisition of Seagen, the Seattle area's biggest biotech company, according to a report in the Wall Street Journal Monday.
- 02/27/2023
|
Warren Buffett's letter to shareholders, Tesla's Investor Day, Pfizer-Seagen deal: 3 things to know
- Yahoo Finance Live's Brad Smith summarizes three key topics in markets to pay attention to on Monday morning.
- 02/27/2023
|
Pfizer in early-stage talks to acquire Seagen: Report
- Yahoo Finance's Anjalee Khemlani joins the Live show to discuss reports that Pfizer is in talks to acquire biotech firm Seagen in a $30 billion deal.
- 02/27/2023
|
Seagen stock opened 13% up on Monday: find out why
- Seagen Inc (NASDAQ: SGEN) opened more than 10% up this morning on reports that Pfizer Inc (NYSE: PFE) is interested in buying the cancer therapies company.
- 02/27/2023
|
'Here We Go Again': Seagen Soars As Pfizer Reportedly Mulls A Takeover
- Pfizer is in early talks to acquire cancer specialist Seagen, according to a report that sent SGEN stock flying on Monday. The post 'Here We Go Again': Seagen Soars As Pfizer Reportedly Mulls A Takeover appeared first on Investor's Business Daily.
- 02/27/2023
|
Pfizer in talks to acquire biotech firm Seagen for $30 billion: Report
- Yahoo Finance Live's Julie Hyman reports that Pfizer is looking to acquire biotech firm Seagen in a $30 billion takeover deal.
- 02/27/2023
|
Seagen (SGEN) Likely to be Acquired by Pfizer Claims WSJ
- Seagen (SGEN) may be acquired by the large-cap pharma company Pfizer at a valuation of more than $30 billion, according to a Wall Street Journal article. Seagen's stock is up 17% in pre-market hours in response to the news.
- 02/27/2023
|
Seagen stock jumps on Pfizer takeover talk
- Pfizer Inc (NYSE:PFE) is reportedly in talks to buy Seagen Inc (Seattle Genetics, Inc. (NASDAQ:SGEN)), a cancer drug maker that was last year tied to a potential takeover by Merk before negotiations broke down. Seagen shares shot up some 13% in pre-market deals to trade at US$182.99 following a Wall Street Journal report on Sunday claiming early-stage takeover talks were underway, citing ‘people familiar with the matter'.
- 02/27/2023
|
Seagen's stock surges 15% after a report that Pfizer is in talks to buy the cancer-focused biotech
- Pfizer is in early talks to acquire cancer drugmaker Seagen in a potentially multibillion-dollar deal, The Wall Street Journal reported Monday.
- 02/27/2023
|
Seagen to Present at the Cowen 43rd Annual Health Care Conference
- BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced that management will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 1:30 p.m. Eastern Time. The presentation will be webcast live and available for replay from the investor section of Seagen's website at investor.seagen.com.
- 02/27/2023
|
Seagen's stock soars on reported Pfizer buyout interest; Union Pacific shares rally after CEO ouster
- Here are some of the most active stocks in the premarket on Monday. U.S. stock futures ES00, +0.50% were pointing to an advance after the worst week for the S&P 500 SPX, -1.05% since the period that ended Dec. 9.
- 02/27/2023
|
Pfizer in Talks to Buy Seagen for $30 Billion or More
- The deal would strengthen Pfizer's lineup of cancer treatments, The Wall Street Journal reports.
- 02/27/2023
|
Pfizer in talks to buy Seagen for likely for more than $30 bln - WSJ
- Pfizer Inc is in early talks to acquire drugmaker Seagen Inc , the Wall Street Journal reported late on Sunday, citing people familiar with the matter.
- 02/26/2023
|
Pfizer in Early-Stage Talks to Acquire Seagen
- Pfizer Inc. is in talks to acquire biotech Seagen Inc, according to people familiar with the matter, the latest potential deal for a big drug company aimed at adding a promising class of targeted cancer therapies.
- 02/26/2023
|
Why Seagen Stock Is Soaring Today
- Investors and analysts liked what they heard in the company's Q4 update.
- 02/16/2023
|
Seagen's (SGEN) Q4 Earnings & Sales Beat Estimates, Stock Up
- Seagen (SGEN) reports better-than-expected results in the fourth quarter of 2022, beating both earnings and sales estimates. Stock up in the after-market hours in response to the news.
- 02/16/2023
|
Seagen Inc. (SGEN) Q4 2022 Earnings Call Transcript
- Seagen Inc. (NASDAQ:SGEN ) Q4 2022 Results Conference Call February 15, 2023 4:30 PM ET Company Participants Doug Maffei - VP, IR David Epstein - CEO Chip Romp - EVP, Commercial U.S. Todd Simpson - CFO Roger Dansey - President, R&D Conference Call Participants Salveen Richter - Goldman Sachs Matthew Harrison - Morgan Stanley Jessica Fye - JP Morgan Jay Olson - Oppenheimer Steven Willey - Stifel Gregory Renza - RBC Capital Markets Yige Guo - Guggenheim Securities Andy Hsieh - William Blair Joe Catanzaro - Piper Sandler Andrew Berens - SVB Securities Dane Leone - Raymond James Operator Good day everyone and welcome to the Seagen Fourth Quarter and Full Year 2022 Conference Call. [Operator Instructions] Please also note, today's event is being recorded.
- 02/15/2023
|
Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates
- Seattle Genetics (SGEN) delivered earnings and revenue surprises of 21.57% and 9.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/15/2023
|
4 Biotech Stocks Set to Outpace Q4 Earnings Estimates
- Let us look at some biotech stocks, ALLO, EDIT, NTLA and SGEN that are poised to beat on fourth-quarter earnings.
- 02/03/2023
|
Seagen's (SGEN) Tukysa Gets Accelerated FDA Nod for New Indication
- The FDA grants accelerated approval to Seagen's (SGEN) Tukysa in combination with trastuzumab for previously treated HER2-positive metastatic colorectal cancer.
- 01/20/2023
|
Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023
- BOTHELL, Wash.--( BUSINESS WIRE )--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its fourth quarter and full year 2022 financial results on Wednesday, February 15, 2023 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update.
- 01/19/2023
|
100 Best Stocks Of 2022: Oil Stocks And Medicals Shine
- Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business Daily.
- 12/30/2022
|
Seagen: 2023 Shaping Up To Be A Breakout Year
- SGEN has been under pressure since a rumored takeover deal by pharmaceutical giant Merck & Co. fell through last summer. The company last reported its Q3 earnings with stronger than expected sales, with an expectation of further topline momentum into 2023.
- 12/22/2022
|
Top Stocks In Multiple Industries Build Bases As Market Gains Strength
- An array of top stocks in a wide variety of industries are building cup bases as the stock market recovers. The post Top Stocks In Multiple Industries Build Bases As Market Gains Strength appeared first on Investor's Business Daily.
- 12/02/2022
|
These Are the Five Best and Worst Performing Healthcare Stocks in October 2022
- The healthcare sector has gained momentum following the COVID-19 pandemic. Several companies gained early regulatory approval for developing COVID-19 drugs and distributing vaccines.
- 11/28/2022
|
Hot Biotech Stocks Rise Into Leadership; Pass Buy Points Or Build Bases
- Top biotech stocks surge within the IBD 50. Some pass buy points while others build bases.
- 11/25/2022
|
Seagen (SGEN) Adcetris Label Expansion OK'd, New CEO Named
- The FDA approves Seagen's (SGEN) Adcetris for a new indication, treating pediatric patients with previously untreated high-risk Hodgkin lymphoma. The company also appoints a new CEO.
- 11/11/2022
|
Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles
- Biogen and Seagen tapped new CEOs on Thursday but the biotech stocks diverged following the long-anticipated announcements. The post Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles appeared first on Investor's Business Daily.
- 11/10/2022
|
Final Trades: Honeywell, XPO Logistics, Seagen & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 10/31/2022
|
Seagen Inc. (SGEN) Q3 2022 Earnings Call Transcript
- Seagen Inc. (NASDAQ:SGEN ) Q3 2022 Earnings Conference Call October 27, 2022 4:30 PM ET Company Participants Doug Maffei - Vice President, Investor Relations Roger Dansey - Interim Chief Executive Officer and Chief Medical Officer Todd Simpson - Chief Financial Officer Chip Romp - Executive Vice President, Commercial U.S. Conference Call Participants Michael Schmidt - Guggenheim Andrew Berens - SVB Securities Jeff Hung - Morgan Stanley Jay Olson - Oppenheimer Gregory Renza - RBC Capital Markets Andy Hsieh - William Blair Operator Good day and welcome to the Seagen Third Quarter 2022 Financial Results Conference Call. [Operator Instructions] Please note, today's event is being recorded.
- 10/27/2022
|
Seattle Genetics (SGEN) Reports Q3 Loss, Tops Revenue Estimates
- Seattle Genetics (SGEN) delivered earnings and revenue surprises of -11.96% and 8.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 10/27/2022
|
Is Seagen Stock a Buy Now?
- It's growing faster than competitors, but headwinds might soon bog it down.
- 10/12/2022
|
Seagen: A Stellar Portfolio Anchor
- As it successfully transitioned into a commercial-stage operator, Seagen is enjoying great progress. The four drugs powering Seagen's marketed portfolio are generating robust revenue growth.
- 10/04/2022
|
Will Seagen's (SGEN) Portfolio of Drugs Help Combat Rivalry?
- Seagen (SGEN) expects its portfolio of marketed drugs, which are approved for various cancer indications, to generate incremental sales and combat stiff competition.
- 10/04/2022
|
Standalone Seagen Is Starting To Look Attractive
- Seagen is now trading below the levels that implied a high probability of a buyout. Label expansion opportunities for approved products and the expanding pipeline will drive strong topline growth in the following years.
- 09/30/2022
|
Seagen: Upcoming Short- And Medium-Term Clinical Catalysts
- Only one future study readout was talked about in Seagen's Q2 earnings call. However, six additional human trials are estimated to complete in the next 6 months.
- 09/30/2022
|
Virtus' Joe Terranova offers his volatility playbook
- Joe Terranova, Virtus Investment Partners chief market strategist, joins 'Closing Bell: Overtime' to discuss CNBC's Alpha Survey results and where he's looking in the market now.
- 09/27/2022
|
Seagen (SGEN) Inks Deal With LAVA Therapeutics for LAVA-1223
- Seagen (SGEN) signs an exclusive agreement with LAVA Therapeutics to develop and commercialize the latter's preclinical asset, LAVA-1223, targeting EGFR-expressing solid tumors.
- 09/27/2022
|
Worried About the Stock Market? Take Warren Buffett's Advice and Do This
- The billionaire investor is a big believer in betting on America.
- 09/22/2022
|
15 Stocks Billionaire Investors Agree It's Smart To Buy Now
- Big investors are famous for breaking rank from the S&P 500 crowd. So when you see a few agreeing on a stock, it's worth paying attention.
- 09/12/2022
|
Merck's Deal With Seagen May Have Fallen Through. Now What?
- A steep valuation may force Merck to look elsewhere for portfolio growth.
- 09/07/2022
|
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
- The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
- 08/31/2022
|
Merck Looks Attractive, With or Without Seagen
- While investors are eagerly awaiting news on a Seagen tie-up, Merck offers upside even if the deal doesn't materialize.
- 08/24/2022
|
Does Merck Finally Have The Fodder It Needs To Buy Seagen?
- Seagen lost a royalty battle Friday, but SGEN stock jumped on the potential the rumored Merck acquisition could be looming. The post Does Merck Finally Have The Fodder It Needs To Buy Seagen?
- 08/12/2022
|
Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe
- Seagen (SGEN) focuses on improving sales of its marketed drugs approved for different types of cancer indications. Stiff competition in the market remains a woe.
- 08/11/2022
|
Get ready for more merger mania in pharma sector the rest of the year
- Pfizer Inc.'s PFE, +0.24% $5.4 billion acquisition of Global Blood Therapeutics Inc. GBT, +0.02% is the latest sign that cash-flush drug makers are ready to jump back into dealmaking.
- 08/09/2022
|
These eight health-care stocks can keep you invested in the market with less worry
- You're tempted to increase exposure to stocks because of the market's strength. But you're still gun shy because of the painful selloff.
- 08/02/2022
|
Seagen's (SGEN) Earnings & Revenues Surpass Estimates in Q2
- Seagen (SGEN) reports a narrower-than-expected loss in the second quarter of 2022 while its revenues beat estimates.
- 07/29/2022
|
Seagen Inc. (SGEN) CEO Roger Dansey on Q2 2022 Results - Earnings Call Transcript
- Seagen Inc. (NASDAQ:SGEN ) Q2 2022 Earnings Conference Call July 28, 2022 4:30 PM ET Company Participants Douglas Maffei - Vice President of Investor Relations Roger Dansey - Chief Medical Officer & Interim Chief Executive Officer Todd Simpson - Chief Financial Officer Chip Romp - Executive Vice President, Commercial U.S. Conference Call Participants Salveen Richter - Goldman Sachs Matthew Harrison - Morgan Stanley Cory Kasimov - JPMorgan Gena Wang - Barclays Andrew Berens - SVB Securities Michael Schmidt - Guggenheim Geoff Meacham - Bank of America Gregory Renza - RBC Capital Stephen Willey - Stifel Andy Hsieh - William Blair Joe Catanzaro - Piper Sandler Jay Olson - Oppenheimer Zhiqiang Shu - Berenberg Reni Benjamin - JMP Securities Ami Fadia - Needham Operator Good day and welcome to the Seagen Second Quarter 2022 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded.
- 07/28/2022
|
Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates
- Seattle Genetics (SGEN) delivered earnings and revenue surprises of 10.98% and 12.26%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 07/28/2022
|
Seagen Tips Its Hand In Bladder Cancer, But Is It Enough To Woo Merck?
- Nearly two-thirds of bladder cancer patients responded to a combination from Seagen and Merck, leading SGEN stock to jump Tuesday. The post Seagen Tips Its Hand In Bladder Cancer, But Is It Enough To Woo Merck?
- 07/26/2022
|
Seagen shares positive data for bladder cancer drug; stock is up 2.5%
- Shares of Seagen Inc. SGEN, +0.71% gained 2.5% in premarket trading on Tuesday after the company said an early-stage clinical trial evaluating its investigational treatment for urothelial cancer in combination with Merck & Co. Inc.'s MRK, +0.47% Keytruda met its primary endpoint. Seagen is developing the therapy, enfortumab vedotin, with Astellas Pharma Inc. jp:TSE:4503 ; it received a Breakthrough Therapy designation in early 2020.
- 07/26/2022
|
Merck deal for Seagen unlikely to be finalized ahead of earnings later this month, sources say
- Merck & Co.'s roughly $40 billion deal for Seagen Inc. is unlikely to be finalized ahead of the pharmaceutical giant's earnings later this month, though the talks remain on track, according to people familiar with the matter.
- 07/15/2022
|
Seattle Genetics (SGEN) Now Trades Above Golden Cross: Time to Buy?
- Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
- 07/13/2022
|
Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2022 Financial Results on July 28, 2022
- BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its second quarter 2022 financial results on Thursday, July 28, 2022 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update. Conference call and webcast information: Telephone 844-763-8274 (U.S.) or +1 412-717-9224 (international); conference ID 101
- 07/08/2022
|
The direction of M&A in biotech is very, very vast, says Oppenheimer's Holz
- Jared Holz, Oppenheimer healthcare equity strategist, joins 'Power Lunch' to discuss the possibility of M&A in the healthcare sector, if investors remain focused on the oncology side of healthcare businesses and more.
- 07/07/2022
|
Merck nears Seagen takeover: ‘question is how does FTC look at this?'
- Shares of Seagen Inc (NASDAQ: SGEN) are up 3.0% this morning on a report that Merck & Co Inc (NYSE: MRK) is in advanced talks to buy the cancer drug specialist for at least $40 billion. Dr Gottlieb reacts to the news According to the Wall Street Journal, the pharma giant is willing to pay […] The post Merck nears Seagen takeover: ‘question is how does FTC look at this?
- 07/07/2022
|
Seagen (SGEN) Stock Pops on Merck Buyout Rumors
- Seagen (SGEN) stock is getting a boost on Thursday as rumors circulate that Merck (MRK) is considering a buyout of the biotechnology company. The post Seagen (SGEN) Stock Pops on Merck Buyout Rumors appeared first on InvestorPlace.
- 07/07/2022
|
Merck nears $40 billion deal for Seagen, report says
- Pharma giant Merck is in advanced talks to acquire biotech Seagen in a deal valued at roughly $40 billion, according to a Wall Street Journal report.
- 07/07/2022
|
Merck in advanced talks to buy biotech company Seagen
- Yahoo Finance Live anchors discuss reports of an acquisition deal between Merck and Seagen.
- 07/07/2022
|
Why Merck Is Sending Seagen Stock Higher Today
- Seagen Inc (NASDAQ: SGEN) shares are trading higher Thursday following reports suggesting Merck & Company Inc (NYSE: MRK) is in advanced talks to acquire the company. According to a Wall Street Journal report citing people familiar with the matter, the two companies are.
- 07/07/2022
|
Merck's Potential Buyout Of Seagen Expected Within Next Few Weeks: Report
- Merck & Co Inc (NYSE: MRK) is in advanced talks to acquire Seagen Inc (NASDAQ: SGEN), and an agreement on a purchase is expected in the next few weeks, Wall Street Journal reported citing people familiar with the matter. The potential deal could be worth roughly $40.
- 07/07/2022
|
Merck in talks to buy cancer biotech Seagen: report
- Merck & Co is reportedly in talks to acquire biotech company Seagen Inc. in a nearly $40 billon deal that would add to the company's cancer drug portfolio.
- 07/07/2022
|
Merck in advanced talks to buy Seagen in $40-billion deal - WSJ
- Drugmaker Merck & Co is in advanced talks to buy cancer-focused biotech company Seagen Inc in a deal that could be worth roughly $40 billion or more, the Wall Street Journal reported on Wednesday.
- 07/06/2022
|
Trial Results Set to Make or Break Small-Cap Pharma Stocks
- One analyst is putting the odds at three to one that tests of a Karuna Therapeutics Inc. ( KRTX , Financial) schizophrenia drug will meet study objectives, paving the way to Food and Drug Administration approval. If that happens, Jefferies analyst Chris Howerton believes the treatment should have “no issue” topping annual sales of $1 billion, reported BioPharma Dive.
- 07/06/2022
|
Top 5 Nasdaq Stocks Flying High Amid Index's Bloodbath in 1H
- We have narrowed our search to five Nasdaq Composite listed stocks that have witnessed a double-digit rally year to date. These are: AEP, AZPN, SGEN, DLTR and TMUS.
- 07/05/2022
|
Oncology ABCs: A Small-Cap Biopharma Prospectus Series
- Oncology remains the fastest growing pharma segment, where innovation is largely driven by emerging small companies. The global oncology market is estimated at c US$175–180bn and is anticipated to more than double from current levels within the next seven years to address the rising incidence rates.
- 07/04/2022
|
A Buyout-Driven Pair Trade: Buy Aurinia, Sell Merck (Or Seagen If You Must)
- The most recent two hottest potatoes in the biotech arena are Aurinia Pharmaceuticals and Seagen. While the latter is mostly/recently associated with an upcoming Merck buyout, the former has been associated with many big pharma names.
- 07/04/2022
|
Here's Why Seattle Genetics (SGEN) is a Great Momentum Stock to Buy
- Does Seattle Genetics (SGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 06/30/2022
|
Seagen (SGEN) Up More Than 20% in Past 3 Months: Here's Why
- Seagen (SGEN) is riding on the strong uptake of its marketed drugs that are approved for different cancer indications. Further label expansion of these drugs should boost the top line.
- 06/29/2022
|
Investors Need Not Be Alarmed by Drug Patent Expirations
- Investors who are sweating the loss of patent protection for some of Big Pharma's top-selling drugs should relax.
- 06/28/2022
|
Seagen Would Be A Great Fit For Merck
- Seagen had two setbacks this year - the below-consensus FY2022 guidance and the resignation of CEO Siegall. The stock shot up this month when rumors surfaced that Merck is interested in acquiring the company.
- 06/26/2022
|
Should You Sell Biotech Stocks If There's a Recession?
- It's probably better to think about whether to buy more shares.
- 06/23/2022
|
Seagen (SGEN) Stock Up on Rumors of Acquisition by Merck
- Shares of Seagen (SGEN) rise after rumors of a buyout by Merck hit the market. However, a deal is not imminent at the moment.
- 06/20/2022
|
Seattle Genetics (SGEN) Moves 12.7% Higher: Will This Strength Last?
- Seattle Genetics (SGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- 06/20/2022
|
Merck reportedly eyeing acquisition of Seattle biotech giant Seagen
- Biopharma giant Merck is considering an acquisition of Seagen, the Seattle area's biggest biotech company, according to a report in the Wall Street Journal Friday.
- 06/17/2022
|
Why Seagen Surged Today
- Merck is thinking about whether it's an appealing acquisition target.
- 06/17/2022
|
Seagen Shares Pop on Rumors of Merck Acquisition
- Shares of Seagen Inc. ( SGEN , Financial) climbed more than 16% to about $170 on Friday as investors piled into the stock on rumors the company was being eyed by Merck & Co. Inc. ( MRK , Financial). A deal seems to make sense given the two pharmaceutical companies have been partners since 2020.
- 06/17/2022
|
SGEN Stock Alert: Is Merck About to Buy Seagen?
- Today, various reports have highlighted a potential deal for Merck to buy out Seagen, taking SGEN stock on a nice ride this afternoon. The post SGEN Stock Alert: Is Merck About to Buy Seagen?
- 06/17/2022
|
Merck Shows Takeover Interest In Seagen: WSJ
- Merck & Co Inc (NYSE: MRK) is reportedly mulling buying cancer-focused biotech Seagen Inc (NASDAQ: SGEN), Wall Street Journal reported citing people familiar with the matter. If the deal happens, it would be significant, given Seagen's market value of roughly $28.
- 06/17/2022
|
Merck considering purchase of cancer drug maker Seagen - WSJ
- Drugmaker Merck & Co is considering buying cancer-focused biotech company Seagen Inc, the Wall Street Journal reported on Friday, citing people familiar with the matter.
- 06/17/2022
|
Seagen's stock surges after WSJ reports $31 billion-valued biotech is being eyed by Merck
- Shares of Seagen Inc. SGEN, +12.02% shot up 14.7% toward a seven-month high in morning trading Friday, after The Wall Street Journal reported that Merck & Co. Inc. MRK, -0.02% is looking into buying the cancer-focused biotechnology company. Meanwhile, drug-maker Merck's stock eased 0.2%.
- 06/17/2022
|
5 Growth Stocks to Buy Now
- EPS estimates are generally a strong indication of future growth. That's just one part of finding reliable growth stocks.
- 05/27/2022
|
Seagen (SGEN) Posts Positive Data from New Study on Tukysa
- Seagen (SGEN) reports favorable data on the pivotal phase II MOUNTAINEER study evaluating Tukysa in combination with Herceptin for treating HER2-positive metastatic colorectal cancer.
- 05/24/2022
|
Seagen's (SGEN) Stock Up on CEO's Resignation Announcement
- Seagen's (SGEN) current chief executive officer and president, Clay Siegall, announces his resignation. The company is looking for a new CEO.
- 05/17/2022
|
Seagen says CEO has resigned
- Shares of Seagen Inc. SGEN, +3.22% were up 2.4% in trading on Monday after the company said its president and CEO Clay Siegall has resigned. Seagen had announced last week that Siegall would take a leave of absence after he was allegedly involved in a domestic violence incident at his home.
- 05/16/2022
|
2 Cheap Growth Stocks Near Their 52-Week Lows to Buy and Forget
- Buying these stocks on the dip could result in big returns for investors.
- 05/16/2022
|
What Stocks To Buy This Week? 4 Biotech Stocks To Know
- Should investors pay more attention to these biotech stocks?
- 05/15/2022
|
Seagen: Brewing Blockbusters
- Seagen is a phenomenal innovation success story that delivers hope to patients afflicted by deadly cancers while also rewarding shareholders. The approved therapeutics should generate at least $1.6B in revenue this year. Due to various ongoing label expansions, you can expect a much stronger top-line growth rate.
- 05/09/2022
|
3 Unstoppable Stocks to Buy in May
- These big drugmakers should be long-term winners.
- 05/07/2022
|
5 Graham's Lost Formula Biotech Stocks to Consider for May
- After a brutal month in April, U.S. market indexes were lower on Tuesday as investors await the Federal Open Market Committee's decision on interest rates.
- 05/03/2022
|
3 Top Biotech Stocks To Watch In May 2022
- Which biotech stocks do you have on your May 2022 watchlist?
- 05/02/2022
|
Seagen's (SGEN) Q1 Earnings & Revenues Surpass Estimates
- Seagen (SGEN) reports narrower-than-expected loss in the first quarter of 2022 while its revenues beat estimates.
- 04/29/2022
|
Seagen Inc. (SGEN) CEO Clay Siegall on Q1 2022 Results - Earnings Call Transcript
- Seagen Inc. (NASDAQ:SGEN ) Q1 2022 Earnings Conference Call April 28, 2022 4:30 PM ET Company Participants Peggy Pinkston - Senior Vice President of Investor Relations Clay Siegall - President & Chief Executive Officer Todd Simpson - Chief Financial Officer Chip Romp - Executive Vice President, Commercial U.S. Roger Dansey - Chief Medical Officer Conference Call Participants Cory Kasimov - JPMorgan Salveen Richter - Goldman Sachs Andrew Berens - SVB Michael Schmidt - Guggenheim Gena Wang - Barclays Andy Hsieh - William Blair Jay Olson - Oppenheimer Reni Benjamin - JMP Securities Zhiqiang Shu - Berenberg Joe Catanzaro - Piper Sandler Operator Good day, and welcome to the Seagen First Quarter 2022 Financial Results Conference Call. All participants will be in a listen-only mode.
- 04/28/2022
|
Biotech giant Seagen reveals plans for 270K square-foot manufacturing facility near Seattle
- Seagen is expanding its manufacturing capacity in the Seattle area.
- 04/20/2022
|
Seagen (SGEN) Gets Nod From EU for Bladder Cancer Drug, Padcev
- The European Commission approves Seagen's (SGEN) Padcev as a monotherapy for treating adult patients with locally advanced/metastatic urothelial cancer.
- 04/14/2022
|
Top Stocks To Buy This Week
- We've crunched the data to bring you the best and boldest Top Stocks from last week's winners and losers.
- 04/12/2022
|
9 Wave Setups To Watch (Video)
- Some of these stocks present long opportunities as they pull back.
- 04/01/2022
|
Tekla Healthcare Investors: A Dividend Paymaster That Can Compensate For Poor Price Performance
- Tekla Healthcare Investors: A Dividend Paymaster That Can Compensate For Poor Price Performance
- 03/29/2022
|
Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe
- Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.
- 03/16/2022
|
Seagen: Bad Forecast But Good Investment
- Seagen released mixed quarterly results and a weak outlook for 2022.
- 03/12/2022
|
Seagen: Long-Term Pharma Stock To Own Based On Sales Growth And Oncology Portfolio
- Seagen had achieved net product sales of $1.4 billion in 2021, which was an annual growth rate of 38%.
- 03/12/2022
|
Astellas Worth A Look On Revenue Re-Acceleration Potential
- Astellas Worth A Look On Revenue Re-Acceleration Potential
- 03/09/2022
|
Steven Cohen's Interest in IDEAYA Increases
- Steven Cohen (Trades, Portfolio), leader of Point72 Asset Management, disclosed earlier this week he increased his stake in IDEAYA Biosciences Inc. ( IDYA , Financial) by 52.12%.
- 02/25/2022
|
Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients
- Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) announced the initial results from Cohort H of the EV-103 trial investigating PADCEV (enfortumab vedotin-ejfv) in muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy. Data will be presented at the 2022 ASCO Genitourinary Cancers Symposium (ASCO GU).
- 02/15/2022
|
Nasdaq 100 suffers broad selloff, led by biotech Seagen and tech heavyweights
- The Nasdaq 100 NDX, -2.08% slumped 1.7% in afternoon trading Thursday, with only 17 of its components gaining ground, after the technology-friendly index ran up 3.3% over the past two days. The index's biggest gainer was Datadog Inc. stock DDOG, +12.28% , which shot up 14.3% over the monitoring and security software platform company reported before the open better-than-expected fourth-quarter results and provided an upbeat first-quarter sales outlook.
- 02/10/2022
|
Seagen (SGEN) Q4 Earnings Miss, Revenues Top Mark, Stock Down
- Seagen (SGEN) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock falls in after-hours trading.
- 02/10/2022
|
Here's Why Seagen Stock Is Falling Today
- Investors aren't happy about disappointing forward guidance.
- 02/10/2022
|
Seagen Inc. (SGEN) CEO Clay Siegall on Q4 2021 Results - Earnings Call Transcript
- Seagen Inc. (SGEN) CEO Clay Siegall on Q4 2021 Results - Earnings Call Transcript
- 02/09/2022
|
Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates
- Seattle Genetics (SGEN) delivered earnings and revenue surprises of -20.25% and 6.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/09/2022
|
Best Biotech Stocks to Invest in Now
- Try your hand at morphing science and business for a great investment opportunity in biotech.
- 01/28/2022
|
Seagen's SEA-CD40 Combo Regime Shows Preliminary Antitumor Activity In Pancreatic Cancer
- Seagen Inc (NASDAQ: SGEN) announced data from a Phase 1 trial combining SEA-CD40 with chemotherapy and an anti-PD-1 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). The data were shared at the ASCO GI annual meeting.
- 01/19/2022
|
Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2021 Financial Results on February 9, 2022
- BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its fourth quarter and full year 2021 financial results on Wednesday, February 9, 2022 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update. Conference call and webcast information: Telephone 844-763-8274 (U.S.) or +1 412-717-9224 (international);
- 01/18/2022
|
Pieris Is A Biotech To Watch With Extensive Pipeline And Key Partnerships
- Pieris Is A Biotech To Watch With Extensive Pipeline And Key Partnerships
- 01/15/2022
|
4 Biotech Acquisitions We'd Like to See in 2022
- These potential corporate combinations would make a lot of sense.
- 01/14/2022
|
Seagen: SEA-CD40 Is The Next Growth Driver
- LV and SEA-CD40 represent the nearest growth drivers. A short-term positive could be a win in a patent dispute with Daiichi. According to my valuation, Seagen's target price is $193.
- 12/23/2021
|
Seagen (SGEN) Gets Positive CHMP Opinion for Bladder Cancer Drug
- The CHMP gives a positive opinion on, and recommends approval to Seagen's (SGEN) Padcev as a monotherapy for treating adult patients with locally advanced/metastatic urothelial cancer.
- 12/20/2021
|
SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline
- SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline
- 12/14/2021
|
3 Biotech Stocks That Could Make You Richer in December (and Beyond)
- These stocks could be just what you need to put in your stocking.
- 12/12/2021
|
Got $1,000? These 3 Stocks Could Be Bargain Buys for 2022 and Beyond
- Sales are climbing at these biotech companies -- and more potential products are on the horizon.
- 12/10/2021
|
Seagen Tukysa Maintains Survival Benefit, Delays Cancer Progression In The Brain In Breast Cancer Patients
- Seagen Inc (NASDAQ: SGEN) has revealed new data from exploratory analyses from the HER2CLIMB trial of Tukysa (tucatinib) combined with trastuzumab & capecitabine in HER2-positive metastatic breast cancer with stable or active brain metastases. The data were featured at the 2021 San Antonio Breast Cancer Symposium.
- 12/09/2021
|
Why This Investor Is Selling His Seagen Shares
- Having fallen more than 22% over the last month, Seagen Inc (NASDAQ: SGEN) shares are now trading down about 15% year-to-date. With Seagen stock seemingly stuck in a downtrend, Virtus Investment Partners' Joe Terranova decided to cut his position.
- 12/06/2021
|
Why Affirmed Stock Was Up More Than 12% Wednesday
- Positive trial results regarding the company's pipeline are buoying the stock's price.
- 11/17/2021
|
3 Biotech Stocks That Could Make You Richer
- The best may be yet to come for these companies.
- 10/30/2021
|
Seagen (SGEN) Q3 Loss Widens, Revenues Beat, 2021 Guidance Up
- Seagen's (SGEN) earnings miss estimates in the third quarter of 2021 while revenues beat the same. The company increases its financial guidance for 2021.
- 10/29/2021
|
Seagen Inc. (SGEN) CEO Clay Siegall on Q3 2021 Results - Earnings Call Transcript
- Seagen Inc. (SGEN) CEO Clay Siegall on Q3 2021 Results - Earnings Call Transcript
- 10/28/2021
|
Seattle Genetics (SGEN) Reports Q3 Loss, Tops Revenue Estimates
- Seattle Genetics (SGEN) delivered earnings and revenue surprises of -187.50% and 9.68%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 10/28/2021
|
Why Seagen (SGEN) Might Surprise This Earnings Season
- Seagen (SGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 10/27/2021
|
Seattle Genetics's Earnings Outlook
- Seattle Genetics (NASDAQ:SGEN) is set to give its latest quarterly earnings report on Thursday, 2021-10-28. Here's what investors need to know before the announcement.
- 10/27/2021
|
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
- Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new molecular entities, or NMEs, were approved in September.
- 10/01/2021
|
Japan's MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
- TOKYO and BOTHELL, Wash., Sept. 27, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D.
- 09/27/2021
|
Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer (Revised)
- The FDA grants accelerated nod to Seagen (SGEN) and Genmab's Tivdak for treating adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
- 09/22/2021
|
Seagen, Inc. (SGEN) FDA approval of TIVDAK Conference Call (Transcript)
- Seagen, Inc. (SGEN) FDA approval of TIVDAK Conference Call (Transcript)
- 09/21/2021
|
Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer
- The FDA grants accelerated nod to Seagen (SGEN) and Genmab's Tivdak for treating adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
- 09/21/2021
|
FDA Gives Accelerated Approval to Seagen - Genmab's ADC In Cervical Cancer
- The FDA handed an accelerated approval to Seagen Inc (NASDAQ: SGEN) and Genmab A/S' (NASDAQ: GMAB) Tivdak (tisotumab vedotin-tftv, or TV). The nod comes for second-line patients with recurrent or metastatic cervical cancer who previously progressed after chemotherapy rather than PD-(L)1 systemic therapy.
- 09/21/2021
|
Seagen to Host Conference Call and Webcast Discussion on September 21, 2021 to Discuss TIVDAK™ (tisotumab vedotin-tftv) Approval
- BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) will host a conference call and webcast on Tuesday, September 21, 2021 to discuss the U.S. Food and Drug Administration approval of TIVDAK™ (tisotumab vedotin-tftv). Access to the event can be obtained as follows: September 21, 2021 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time Telephone 844-763-8274 (U.S.) or +1 412-717-9224 (international); conference ID 10160278 Webcast with slides will be available at www.seagen.com in the Invest
- 09/20/2021
|
Seagen, Genmab Present Tisotumab Vedotin Combo Data In Cervical Cancer
- Seagen Inc (NASDAQ: SGEN) and Genmab A/S (NASDAQ: GMAB) have interim data from two Phase 1b/2 innovaTV 205 trial cohorts. The trial is evaluating its antibody-drug conjugate tisotumab vedotin (TV) in recurrent or metastatic cervical cancer.
- 09/20/2021
|
Genmab and Seagen Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021
|
Seagen Stock Is A Buy For Its Pipeline Value
- Current revenue and cash support the R&D effort.
- 09/15/2021
|
7 Stocks To Buy To Bet on Underappreciated CEOs
- We hear plenty of stories about overpaid CEOs. Here are seven stocks to buy whose CEOs aren't but still manage to deliver for shareholders.
- 09/10/2021
|
3 Top Healthcare Stocks to Buy for September
- Catalysts are on the horizon for these bargain stocks.
- 09/10/2021
|
Seagen to Highlight Research From 16 Presentations Across Multiple Tumor Types at ESMO 2021
- BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced data and trials in progress from its diverse and growing portfolio of marketed and investigational therapies will be presented at the virtual European Society for Medical Oncology (ESMO) 2021 Annual Meeting, to be held from September 16-21. Sixteen presentations will demonstrate the breadth of Seagen's portfolio and development activities, across multiple cancer types - including a mini oral presentation featuring resul
- 09/08/2021
|
Which Biotech Stock Will Shock the Market in 2022?
- Over the last few years, three tiny biotechs emerged out of nowhere to give amazing returns to early investors. Which biotech might pull off a similar feat in 2022?
- 08/27/2021
|
Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin
- BOTHELL, Wash. & YANTAI, China--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and RemeGen Co., Ltd. (9995.HK), a leading innovative biopharmaceutical company in China, today announced that the two companies have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted ADC. Disitamab vedotin combines the drug-linker technology originally developed by Seagen w
- 08/09/2021
|
Seagen (SGEN) Q2 Earnings Beat Estimates, Revenues Surge Y/Y
- Seagen (SGEN) reports narrower-than-expected loss for the second quarter of 2021 while revenues beat estimates.
- 07/30/2021
|
Seagen's (SGEN) CEO Clay Siegall on Q2 2021 Results - Earnings Call Transcript
- Seagen's (SGEN) CEO Clay Siegall on Q2 2021 Results - Earnings Call Transcript
- 07/29/2021
|
Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates
- Seattle Genetics (SGEN) delivered earnings and revenue surprises of 22.95% and 9.24%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 07/29/2021
|
Seagen (SGEN) Gets Regular Approval, Label Expansion for Padcev
- Seagen and Astellas' two sBLAs for Padcev get FDA approval for patients with locally advanced or metastatic urothelial cancer. The approval comes one month before the PDUFA date of Aug 17, 2021.
- 07/12/2021
|
U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer
- TOKYO and BOTHELL, Wash., July 9, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.
- 07/09/2021
|
This Risky Micro-Cap Could Pay Off Big
- Pieris Pharmaceuticals is introducing a whole new class of drugs to the marketplace.
- 06/30/2021
|
Seagen: Substantially More Growth For This Stalwart
- Despite its sizable capitalization, you can expect more upsides from Seagen due to many label expansions and novel therapeutic development programs. As a group, the three commercialized molecules (Adcetris, Padcev, and Tukysa) already garnered blockbuster results.
- 06/20/2021
|
Seagen Announces Long-Term Results from TUKYSA® (tucatinib) Pivotal Trial in Patients with HER2-Positive Breast Cancer During the Virtual Scientific Program of the 2021 ASCO Annual Meeting
- BOTHELL, Wash.--(BUSINESS WIRE)-- #ASCO2021--Seagen Announces Long-Term Results from Pivotal Trial in Patients with HER2-Positive Breast Cancer During the 2021 ASCO Annual Meeting
- 06/03/2021
|
Astellas and Seagen Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy
- TOKYO and BOTHELL, Wash., May 19, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.
- 05/19/2021
|
3 Biotech Stocks You'll Be Glad You Bought at These Prices
- Their revenue prospects are the ticket to future share price performance.
- 05/19/2021
|
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows
- Although they have been struggling recently, these stocks remain attractive buys over the long term.
- 05/12/2021
|
Seagen Inc. (SGEN) CEO Clay Siegall on Q1 2021 Results - Earnings Call Transcript
- Seagen Inc. (SGEN) CEO Clay Siegall on Q1 2021 Results - Earnings Call Transcript
- 05/01/2021
|
Seagen (SGEN) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
- Seagen (SGEN) lags estimates for earnings and revenues in the first quarter of 2021. Shares lose ground in after-hour trading.
- 04/30/2021
|
Recap: Seagen Q1 Earnings
- Shares of Seagen (NASDAQ:SGEN) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 31.63% over the past year to ($0.67), which missed the estimate of ($0.61).
- 04/29/2021
|
Seattle Genetics's Earnings Outlook
- Seattle Genetics (NASDAQ:SGEN) announces its next round of earnings this Thursday, April 29. Here is Benzinga's everything-that-matters guide for this Thursday's Q1 earnings announcement.
- 04/28/2021
|
Will Seattle Genetics (SGEN) Report Negative Earnings Next Week? What You Should Know
- Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/22/2021
|
Seagen's (SGEN) Two sBLAs for Padcev Gets FDA Priority Review
- The FDA accepts Seagen (SGEN) and Astellas' two sBLAs for Padcev under a priority review to treat patients with locally advanced or metastatic urothelial carcinoma. A verdict is pending on Aug 17, 2021.
- 04/20/2021
|
Astellas and Seagen Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
- TOKYO and BOTHELL, Wash., April 19, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.
- 04/19/2021
|
Seagen's (SGEN) Tisotumab Vedotin BLA Gets FDA Priority Review
- The FDA accepts Seagen (SGEN) and Genmab's BLA for tisotumab vedotin under a priority review to treat recurrent/metastatic cervical cancer. A verdict is pending on Oct 10, 2021.
- 04/12/2021
|
Seagen: The New Oncology Hope
- In recent years, Seagen has undergone a transformation from a one-product company to a diversified player in the oncology drug market. The current conservative stock price based on the DCF model is $ 159.
- 04/12/2021
|
Does 2021's Best Biopharma to Work for Belong in Your Portfolio?
- Horizon Therapeutics has a clear path to significant sales growth.
- 04/07/2021
|
Seagen's (SGEN) MAA for Enfortumab Vedotin Gets EMA Acceptance
- The European Medicines Agency accepts Seagen (SGEN) and Astellas Pharma's marketing application for enfortumab vedotin for treating adult patients with advanced/metastatic urothelial cancer.
- 03/29/2021
|
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
- TOKYO & BOTHELL, Wash.--(BUSINESS WIRE)--Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced that a marketing authorization application (MAA) for enfortumab vedotin was accepted by the European Medicines Agency (EMA). The MAA requests review of enfortumab vedotin for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have received a programmed death receptor-1 (PD-1) or progra
- 03/26/2021
|
Moving Average Crossover Alert: Seagen
- Seagen (SGEN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
- 03/15/2021
|
Seattle Genetics (SGEN) Down 12.4% Since Last Earnings Report: Can It Rebound?
- Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock?
- 03/13/2021
|
7 Biotech Stocks With Catalysts That Go Far Beyond Covid-19 Vaccines
- If you think ecommerce and digital banking have accelerated in the past year, then you really need to check out promising biotech stocks. The post 7 Biotech Stocks With Catalysts That Go Far Beyond Covid-19 Vaccines appeared first on InvestorPlace.
- 03/12/2021
|
Seagen Recommends Rejection Of 'Mini-Tender' Offer from TRC Capital Investment Corporation
- BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced that it has been notified of an unsolicited “mini-tender” offer dated February 22, 2021, made by TRC Capital Investment Corporation, an Ontario, Canada corporation, to purchase up to 1,000,000 shares of Seagen's common stock. According to TRC, its “mini-tender” offer price of $151.00 per share was approximately 4.28% below the closing price of Seagen's common stock on February 19, 2021, the last trading day prior to the
- 03/05/2021
|
Seagen (SGEN), Astellas Submit 2 sBLAs to FDA for Urothelial Cancer
- Seagen (SGEN) and Astellas Pharma announced completion of submissions of two sBLAs to the FDA for Padcev in patients with locally advanced or metastatic urothelial carcinoma.
- 02/19/2021
|
Seagen and Astellas Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
- BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced completion of submissions for two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for PADCEV® (enfortumab vedotin-ejfv). One submission, based on the phase 3 EV-301 trial, seeks to convert PADCEV's accelerated approval to regular approval. The second submission, based on th
- 02/18/2021
|
Seagen and Astellas Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy
- BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced results from the second cohort (cohort 2) of patients in the pivotal phase 2 single-arm EV-201 trial. In the trial, 52 percent of patients who received PADCEV® (enfortumab vedotin-ejfv) had an objective response (95 percent Confidence Interval [CI]: 40.8, 62.4) and the median duration of response was 10.9 months (95 percent
- 02/12/2021
|
Seagen (SGEN) Q4 Earnings Beat Estimates, Revenues Rise Y/Y
- Seagen (SGEN) surpasses estimates for earnings and revenues in the fourth quarter of 2020. The company provides revenues guidance for 2021.
- 02/12/2021
|
European Commission Approves Seagen's TUKYSA® (tucatinib) for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
- BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced that the European Commission (EC) has granted marketing authorization for TUKYSA® (tucatinib) in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least two prior anti-HER2 treatment regimens. TUKYSA is an oral, small molecule tyrosine kinase inhibitor (TKI) of HER2, a protein that contributes to cancer ce
- 02/12/2021
|
Seagen' (SGEN) CEO Clay Siegall on Q4 2020 Results - Earnings Call Transcript
- Seagen' (SGEN) CEO Clay Siegall on Q4 2020 Results - Earnings Call Transcript
- 02/11/2021
|
Seattle Genetics (SGEN) Q4 Earnings and Revenues Top Estimates
- Seattle Genetics (SGEN) delivered earnings and revenue surprises of 11.11% and 3.04%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 02/11/2021
|
Seagen (SGEN) Submits BLA to FDA for Cervical Cancer Drug
- Seagen (SGEN) submits a BLA to the FDA for accelerated approval of tisotumab vedotin in patients with recurrent/metastatic cervical cancer, whose disease has progressed on or after chemotherapy.
- 02/11/2021
|
Why Earnings Season Could Be Great for Seagen (SGEN)
- Seagen (SGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 02/10/2021
|
Here's Why Seagen Jumped Higher Today
- The rumor mill took hold in late-day trading.
- 02/05/2021
|
BMEZ: Healthcare Exposure With A ~4% Yield And Growth Potential
- BMEZ delivered solid results throughout 2020, helped by the healthcare sector overall. This fund doesn't just invest in your typical healthcare companies though and tilts towards smaller and private investments.
- 01/30/2021
|
American BriVision: Deep Dive Into Market Potential
- American BriVision: Deep Dive Into Market Potential
- 01/14/2021
|
The Top 3 Biotech Stocks to Buy in 2021
- Revenue growth is just beginning for these companies.
- 01/10/2021
|
Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2020 Financial Results on February 11, 2021
- BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its fourth quarter and full year 2020 financial results on Thursday, February 11, 2021 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: Thursday, February 11, 2021 1:30 p.m. Pacific Time / 4:30 p.m. Eastern T
- 01/07/2021
|
Seagen Earns Top Honors from Key Biotech Publication
- Seagen, Inc. (SGEN) has recently been named Biotech of the Year by leading industry publication Biopharma Dive, and investors would no doubt agree. Shares of the Seattle-area firm are up nearly 65% year-to-date, far outpacing the Nasdaq Biotechnology Index, which has climbed about 28% since the beginning of the year.
- 12/31/2020
|
Seagen to Present at the J.P. Morgan Healthcare Conference
- BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that management will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021 at 2:00 p.m. Eastern Time. The presentation will be webcast live and available for replay from Seagen's website at www.seagen.com in the Investors section. About Seagen Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningfu
- 12/16/2020
|
7 Biotech Stocks To Buy Beyond Covid Vaccine Plays
- It's a relief to know Covid-19 vaccines are on the way. But there are plenty of other great biotechs that have been overlooked in the market frenzy.
- 12/14/2020
|
Seagen Announces Positive CHMP Opinion for TUKYSA® (tucatinib) for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
- BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion recommending the approval of TUKYSA® (tucatinib) in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least 2 prior anti-HER2 treatment regimens. TUKYSA is an oral, small molecule tyro
- 12/11/2020
|
Seagen Highlights TUKYSA® (tucatinib) Data in Breast Cancer at Virtual 2020 San Antonio Breast Cancer Symposium
- BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced the presentation of new data from TUKYSA (tucatinib), its HER2-positive metastatic breast cancer therapy, at the San Antonio Breast Cancer Symposium (SABCS) Virtual Symposium, taking place December 8-11, 2020. Nine abstracts – including two spotlight posters – highlight the company's commitment to addressing unmet needs in breast cancer. “Following this year's FDA approval of TUKYSA, we continue to broadly study if more
- 12/08/2020
|
Seagen Announces Multiple ADCETRIS® (brentuximab vedotin) Presentations at the 2020 ASH Annual Meeting
- BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced multiple ADCETRIS® (brentuximab vedotin) data presentations at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place virtually December 5-8, 2020. Data presentations include five-year updates from the phase 3 ECHELON-1 and ECHELON-2 clinical trials evaluating ADCETRIS plus a chemotherapy combination regimen in frontline advanced stage classical Hodgkin lymphoma (HL) and CD30-expressing
- 12/07/2020
|
3 Top Growth Stocks to Buy on the Dip
- All of these stocks are down more than 10% in the past four weeks.
- 11/14/2020
|
Seagen Inc. Has Struck Gold; Value For Shareholders + 30% Upside
- Seagen have struck gold with its Merck deal, which sees billions in value creation with long-tailed asset returns. Its antibody-drug conjugate segment has seen label expansion into several key oncology domains, driving total revenue volumes into the future.
- 11/01/2020
|
Why Seagen Shares Are Tumbling 12.5% Today
- A broad market sell-off is trumping third-quarter results that outpaced analyst expectations.
- 10/30/2020
|
Seagen's (SGEN) CEO Clay Siegall on Q3 2020 Results - Earnings Call Transcript
- Seagen's (SGEN) CEO Clay Siegall on Q3 2020 Results - Earnings Call Transcript
- 10/30/2020
|
7 Strong Nasdaq Stocks to Buy As They Keep Marching Higher
- Most Nasdaq stocks have seen ups and downs this year. But these seven have weathered the pandemic well and are bound to climb higher soon.
- 10/26/2020
|
